spiron (spironolactone orion) tafla 25 mg
orion corporation - spironolactonum inn - tafla - 25 mg
spiron (spironolactone orion) tafla 50 mg
orion corporation - spironolactonum inn - tafla - 50 mg
valpress comp filmuhúðuð tafla 160/12,5 mg
teva b.v.* - valsartanum inn; hydrochlorothiazidum inn - filmuhúðuð tafla - 160/12,5 mg
valpress comp filmuhúðuð tafla 80/12,5 mg
teva b.v.* - valsartanum inn; hydrochlorothiazidum inn - filmuhúðuð tafla - 80/12,5 mg
ventoline lausn í eimgjafa 1 mg/ml
glaxosmithkline pharma a/s - salbutamolum súlfat - lausn í eimgjafa - 1 mg/ml
wellbutrin retard tafla með breyttan losunarhraða 150 mg
glaxosmithkline pharma a/s - bupropionum hýdróklóríð - tafla með breyttan losunarhraða - 150 mg
wellbutrin retard tafla með breyttan losunarhraða 300 mg
glaxosmithkline pharma a/s - bupropionum hýdróklóríð - tafla með breyttan losunarhraða - 300 mg
alfadexx vet stungulyf, lausn 2 mg/ml
alfasan nederland b.v. - dexamethasonum natríumfosfat - stungulyf, lausn - 2 mg/ml
qaialdo
nova laboratories ireland limited - spironolactone - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 5.
ropivacainhydrochlorid sintetica stungulyf, lausn 7,5 mg/ml
sintetica gmbh - ropivacainum hýdróklóríð - stungulyf, lausn - 7,5 mg/ml